Arrowhead Pharmaceuticals Inc. (ARWR)

28.72
0.14 0.49
NASDAQ : Health Technology
Prev Close 28.86
Open 29.10
Day Low/High 28.67 / 29.10
52 Wk Low/High 10.41 / 36.80
Volume 468.61K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.77B
EPS -0.70
P/E Ratio 64.22
Div & Yield N.A. (N.A)
Arrowhead Submits Application To Begin Phase 2a Trial Of ARC-520 For The Treatment Of Chronic Hepatitis B Infection

Arrowhead Submits Application To Begin Phase 2a Trial Of ARC-520 For The Treatment Of Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of...

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on the Dynamic Polyconjugate (DPC) siRNA delivery technology...

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare In Chronic Hepatitis B

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare In Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it presented new data on ARC-520, its clinical candidate for the treatment of...

Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)

Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced it awarded "inducement" options to two new employees under Rule 5635(c)(4) of the NASDAQ...

First Week Of June 2014 Options Trading For Arrowhead Research (ARWR)

First Week Of June 2014 Options Trading For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options become available this week, for the June 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on ARC-520, its hepatitis B drug candidate, at two upcoming...

Arrowhead Closes Private Offering With Net Proceeds Of $60 Million

Arrowhead Closes Private Offering With Net Proceeds Of $60 Million

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on October 11, 2013 it closed a previously announced private offering of common and...

Arrowhead Prices At-Market Private Offering For $60 Million Net Proceeds

Arrowhead Prices At-Market Private Offering For $60 Million Net Proceeds

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has priced a private offering with net proceeds expected to be $60 million.

Arrowhead Completes Enrollment In Phase 1 Study Of ARC-520 For The Treatment Of Chronic Hepatitis B

Arrowhead Completes Enrollment In Phase 1 Study Of ARC-520 For The Treatment Of Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based...

Some Weekend Folding Money

Some Weekend Folding Money

I'm content to head into the weekend with my short-term book mostly on the cash side.

Biotech Breakouts

Biotech Breakouts

Favorable charts for Celldex, Repligen and Arrowhead Research.

Arrowhead Promotes David Lewis To Chief Scientific Officer

Arrowhead Promotes David Lewis To Chief Scientific Officer

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the promotion of David Lewis, Ph.

Arrowhead Reports Fiscal 2013 Third Quarter Financial Results

Arrowhead Reports Fiscal 2013 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 third quarter ended June 30, 2013.

Arrowhead To Report Fiscal 2013 Third Quarter Financial Results

Arrowhead To Report Fiscal 2013 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 third quarter ended June...

Arrowhead Begins Phase 1 Trial Of RNAi Therapeutic ARC-520 For Treatment Of Chronic Hepatitis B Infection

Arrowhead Begins Phase 1 Trial Of RNAi Therapeutic ARC-520 For Treatment Of Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a Phase 1 clinical trial of ARC-520, the Company’s...

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 ...

5 Health Care Stocks Under $10 to Watch

5 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA

Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, will host an analyst event today in New York City to discuss ARC-520, its RNAi-based candidate designed to treat chronic hepatitis B virus...

Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B

Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus...

Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520

Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will host an analyst and investor event on Monday, March 25, from 12:30 to 2:00 p.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System

Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days ...

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 first quarter ended December 31, 2012.

Arrowhead To Report Fiscal 2013 First Quarter Financial Results

Arrowhead To Report Fiscal 2013 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2013 first quarter ended December 31, 2012, on Wednesday, ...

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA ...

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering.

Arrowhead Reports Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012.

TheStreet Quant Rating: C+ (Hold)